Is Day One Biopharmaceuticals Inc (DAWN) undervalued? · rev $131.2M
Day One Biopharmaceuticals Inc (DAWN) is a biotechnology company listed on US.
This page asks whether Day One Biopharmaceuticals Inc (DAWN) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported DAWN revenue for 2024-12-31 was $131.2M. Net income was -$95.5M. DAWN currently screens at market cap $656.8M.
DAWN currently screens at market cap $656.8M. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new DAWN 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare DAWN to the stock page model before you treat a low multiple as a gift.
Not investment advice.